Humacyte
HUMA
32 hedge funds and large institutions have $77.5M invested in Humacyte in 2021 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 16 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
151% more capital invested
Capital invested by funds: $30.9M → $77.5M (+$46.7M)
68% more call options, than puts
Call options by funds: $6.18M | Put options by funds: $3.69M
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
14% more funds holding
Funds holding: 28 → 32 (+4)
22.26% less ownership
Funds ownership: 29.25% → 6.99% (-22%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCMGA
York Capital Management Global Advisors
New York
|
+$26.2M |
| 2 |
O
OrbiMed
New York
|
+$17.2M |
| 3 |
DCP
Diameter Capital Partners
New York
|
+$10.9M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$8.58M |
| 5 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$5.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$4.1M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$3.06M |
| 3 |
ACM
Altium Capital Management
New York
|
-$2.8M |
| 4 |
CAC
Cowen and Company
New York
|
-$2.45M |
| 5 |
AGM
Alpine Global Management
New York
|
-$2.14M |
HUMA Hedge Fund Activity: Q3 2021 in Review
32 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q3 2021, worth a combined $77.5M — up 151% from $30.9M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new HUMA positions and 16 closed out — a net gain of 4 holders — while 7 added to existing stakes and 1 trimmed.
The largest buyer was York Capital Management Global Advisors, opening a new position worth an estimated $26.2M. The largest seller was Tudor Investment Corp, exiting entirely with an estimated $4.1M sold.
- 32 institutional investors held Humacyte (HUMA) as of Q3 2021, up from 28 in Q2 2021.
- Funds reported $77.5M of Humacyte stock for Q3 2021, up 151% quarter-over-quarter.
- 20 funds opened new Humacyte positions in Q3 2021 and 16 closed out, a net change of +4 holders.
- The largest Humacyte buyer in Q3 2021 was York Capital Management Global Advisors, an estimated $26.2M added.
- The largest Humacyte seller in Q3 2021 was Tudor Investment Corp, an estimated $4.1M sold.
Based on aggregated 13F filings for Q3 2021.